U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine has announced that the U.S. Food and Drug Administration has cleared MYCO-001 in a recent Investigational New Drug (IND) application, marking the first clearance of the company’s drug product.

Category Press Release
Published in Bloomberg

Companies Featured

Mydecine (Mydecine Innovations Group Inc.) is the parent organization of Mindleap, Mydecine Health Sciences, and NeuroPharm.